Home › Valeant, AstraZeneca strike psoriasis deal
 

Keywords :   


Valeant, AstraZeneca strike psoriasis deal

2015-09-01 13:41:52| Biotech - Topix.net

Canada's Valeant Pharmaceuticals International Inc. has struck a deal with AstraZeneca PLC for the rights to sell psoriasis treatment brodalumab after Amgen Inc. dropped its own collaboration with the U.K.-based drug maker over concerns about the drug's side effects. Valeant said on Tuesday that it will pay AstraZeneca $100 million upfront, with another $170 million in prelaunch milestones and up to $175 million following launch.

Tags: deal strike psoriasis astrazeneca

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
02.07Tesla sales rise sharply after slump
02.07Freudenberg Launches Shirt Interlinings Made of Recycled PET
02.07SHIC project to identify research priorities for H5N1 risk to swine
02.07Ohio pork processor cited for 43 safety violations
02.07Greyparrot and VAN DYK Bring AI to MRFs Across the U.S.
02.07Smithfield Foods to shutter Altoona, Iowa ham boning facility
02.07Grove Collaborative Announces New Sustainability Goals, Recommits to Moving the Industry Beyond Plastic
02.07Aldi Chops Off Pineapple Crowns in a New Trial to Save 1,400 Tonnes of Food Waste
More »